Previous Close | 36.41 |
Open | 36.97 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 35.13 - 36.97 |
52 Week Range | 23.45 - 37.91 |
Volume | |
Avg. Volume | 23,248 |
Market Cap | 69.452B |
Beta (5Y Monthly) | 0.29 |
PE Ratio (TTM) | 53.26 |
EPS (TTM) | 0.68 |
Earnings Date | Jul 29, 2024 - Aug 02, 2024 |
Forward Dividend & Yield | 0.39 (1.07%) |
Ex-Dividend Date | Sept 27, 2024 |
1y Target Est | 36.33 |
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.